Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Mettler-Toledo Introduces New Webinar

Published: Friday, October 26, 2012
Last Updated: Friday, October 26, 2012
Bookmark and Share
Webinar explains how pharma manufacturers can optimize fermentation process.

Mettler-Toledo Process Analytics has released a new webinar intended for pharmaceutical producers involved in biofermentation.

The webinar explains how optimal microorganism growth conditions and consequently higher process yield can be achieved through a program of dissolved carbon dioxide measurement and control.

In biopharmaceutical operations, it is important that process reliability is high at all times. Central to this aim is timely measurement of analytical parameters.

Well known key process parameters include pH, dissolved oxygen, and turbidity. Less recognized but of significant importance in fermentation reactors is carbon dioxide.

Dissolved carbon dioxide levels can be indicative of the quality of cellular metabolism.

High levels of CO2 generally equate to high cellular growth; however, if CO2 levels are excessive, they can reach a concentration that is toxic to the microorganisms.

Low CO2 levels lead to a slow growth rate and extended process duration. In-line CO2 measurement systems provide continuous, real-time data on CO2 concentration levels, allowing rapid corrective action when required.

Mettler-Toledo’s on-demand webinar illustrates how dissolved CO2 measurement and control can keep fermentation cultures in their optimal growth range.

This consequently increases process yield and efficiency of the fermentation process.

The webinar also introduces Mettler-Toledo's InPro 5000i dissolved CO2 sensor, which has been designed specifically for the requirements of the pharmaceutical industry. The webinar is available at www.mt.com.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Antibodies Paving the Way to HIV Vaccine
Researchers uncover factors responsible for the formation of broadly neutralizing HIV antibodies in humans.
Tapping Evolution to Improve Biotech Products
Researchers show how 'ancestral sequence reconstruction' can be used to guide engineering of a blood clotting protein.
Vaccine Against Common Cold Achievable
Researchers suggest that a vaccine against rhinoviruses is possible using variant virus vaccines.
New Weapon Against Hard-to-Treat Bacterial Infections
Using peptides, researchers have been able to prevent drug-resistance bacteria from forming abscesses.
Treating Sepsis with Marine Mitochondria
Mitochondrial alternative oxidase from a marine animal combats bacterial sepsis.
Biomolecular Manufacturing ‘On-the-Go’
Wyss Institute team unveils a low-cost, portable method to manufacture biomolecules for a wide range of vaccines, other therapies as well as diagnostics.
Molecular Switch Aids Immune Therapy
Researchers identify strategy to maximise effectiveness of immune therapy through molecular switch controlling immune suppression.
Novavax RSV F Vaccine Fails Phase 3 Trial
Novavax announces topline RSV F Vaccine data from two clinical trials in older adults.
GSK’s Shingles Vaccine Candidate Shows High Efficacy
The vaccine candidate showed high efficacy against shingles and its complications in adults aged 70yrs+ in phase III study.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!